SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Cantor Fitzgerald Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $37

Cantor Fitzgerald initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $37.

Benzinga · 05/19/2020 09:56

Cantor Fitzgerald initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $37.